PAHC

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

Wall Street analysts forecast PAHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAHC is 39.75 USD with a low forecast of 27.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Phibro Animal Health Corp revenue for the last quarter amounts to 363.89M USD, increased 39.73 % YoY.

Phibro Animal Health Corp. EPS for the last quarter amounts to 0.65 USD, increased 282.35 % YoY.

Phibro Animal Health Corp (PAHC) has 2475 emplpoyees as of January 11 2026.

Today PAHC has the market capitalization of 1.60B USD.